Fairmount Funds Management LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 17, 2026, for the 2025 Q4 period, Fairmount Funds Management LLC held in its portfolio 13 assets valued at $1,313,784,318 (i.e. $1.31B).

The most valuable assets in the portfolio included: COGENT BIOSCIENCES INC ($319.80M), APOGEE THERAPEUTICS INC ($154.63M), and SPYRE THERAPEUTICS INC ($131.63M).

The chart below shows the top 10 valuable assets, and the table below shows the top 13 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Fairmount Funds Management LLC Portfolio

COGENT BIOSCIENCES INC

APOGEE THERAPEUTICS INC

SPYRE THERAPEUTICS INC

VIRIDIAN THERAPEUTICS INC

ORUKA THERAPEUTICS INC

DIANTHUS THERAPEUTICS INC

ZENAS BIOPHARMA INC

NUVALENT INC

JADE BIOSCIENCES INC

ENLIVEN THERAPEUTICS INC

Fairmount Funds Management LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
COGENT BIOSCIENCES INC	9003418	319801407	COM
APOGEE THERAPEUTICS INC	2048647	154631876	COM
SPYRE THERAPEUTICS INC	4018101	131632989	COM NEW
VIRIDIAN THERAPEUTICS INC	3914458	121817933	COM
ORUKA THERAPEUTICS INC	3705262	112306491	COM
DIANTHUS THERAPEUTICS INC	2137191	88073641	COM
ZENAS BIOPHARMA INC	2209025	80209698	COM
NUVALENT INC	727563	73185562	COM
JADE BIOSCIENCES INC	4553494	70260412	COM NEW
ENLIVEN THERAPEUTICS INC	3711444	57156238	COM
KINIKSA PHARMACEUTICALS INTL	1319688	54437130	ORD SHS CL A
CRESCENT BIOPHARMA INC.	2747866	32589691	COM
INHIBIKASE THERAPEUTICS INC	8625000	17681250	COM NEW